earnings
TG
NASDAQ · TGTX
TG Therapeutics, Inc.
Healthcare · Biotechnology
$56.09
Up+$1.79 (+3.30%)
Updated Sep 2, 2026, 2:15 AM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.08B
- P/E ratio
- 77.67
- Dividend yield
- 0.00%
- 52-week range
- $26.76 – $59.30
- Volume
- 3.2M
- Avg. volume
- 1.87M
Price performance
TGTX price history
1M range · 20 trading sessions · Daily adjusted prices
TGTX closed at $54.30 after 20 trading sessions, up 11.42% for the selected period.
- Last close
- $54.30
- Period change
- +11.42%
- Period low
- $47.94
- Period high
- $56.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $53.58 | $54.36 | $52.67 | $54.30 | 1.62M |
| Aug 28, 2026 | $55.53 | $55.53 | $53.83 | $53.93 | 1.03M |
| Aug 27, 2026 | $55.00 | $55.97 | $54.15 | $55.72 | 1.22M |
| Aug 26, 2026 | $55.50 | $56.04 | $54.53 | $55.03 | 963.31K |
| Aug 25, 2026 | $56.66 | $57.90 | $54.68 | $55.42 | 1.99M |
| Aug 24, 2026 | $53.19 | $56.49 | $52.00 | $56.01 | 2.85M |
| Aug 21, 2026 | $51.10 | $56.87 | $49.97 | $54.27 | 5.56M |
| Aug 20, 2026 | $51.65 | $53.18 | $50.52 | $50.56 | 2.44M |
| Aug 19, 2026 | $51.62 | $52.335 | $50.71 | $51.69 | 1.29M |
| Aug 18, 2026 | $49.28 | $50.29 | $48.98 | $50.26 | 1.2M |
| Aug 17, 2026 | $48.74 | $49.795 | $48.50 | $49.28 | 1.06M |
| Aug 14, 2026 | $47.27 | $48.925 | $47.27 | $48.74 | 1.07M |
| Aug 13, 2026 | $49.70 | $49.70 | $47.53 | $47.94 | 2.77M |
| Aug 12, 2026 | $50.00 | $50.545 | $49.34 | $49.50 | 2.02M |
| Aug 11, 2026 | $49.29 | $50.35 | $49.00 | $49.90 | 1.5M |
| Aug 10, 2026 | $49.26 | $50.00 | $48.50 | $49.16 | 1.91M |
| Aug 7, 2026 | $49.96 | $50.19 | $49.11 | $49.76 | 1.77M |
| Aug 6, 2026 | $49.99 | $50.60 | $49.465 | $49.55 | 1.4M |
| Aug 5, 2026 | $48.22 | $50.03 | $48.22 | $49.88 | 2.84M |
| Aug 4, 2026 | $46.16 | $49.00 | $45.365 | $48.735 | 2.87M |
Latest TGTX news
The latest Smart Investors Daily articles mentioning TGTX.
Stock researchCompany · Earnings
Loading stock research…